Podcast, No Priors
Powering AI-Driven Drug Discovery with President of Isomorphic Labs Max Jaderberg
About
Max Jaderberg, president of Isomorphic Labs, sets out the case for moving drug discovery from empirical trial and error to computational precision engineering with predictive models that approach experimental accuracy. He explains how AlphaFold showed that a deep-learning model could generalise in biology, why models that compound learning across targets generalise with scale, and how that could raise the probability and speed of success in clinical trials. The conversation covers Isomorphic’s datasets and choice of endpoints, automating biology labs, reducing animal testing with in silico models, drug-design engines that are agnostic to disease area, target class and modality, multidrug combinations that span complex pathways, and molecule optimisation for lifespan and healthspan.